MDGL
Madrigal·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Consensus Rating "Buy"
MACD Death Cross
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Double Bottom
Three Black Crows
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MDGL
Madrigal Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis
Four Tower Bridge, 200 Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania
--
Madrigal Pharmaceuticals, Inc., was established in March 2000 and began operations in July 2001.
Synta Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecule drugs to expand and enhance the lives of patients with serious diseases, including cancer and chronic diseases. The company has two drug candidates in clinical trials for the treatment of various types of cancer and several drug candidates in the preclinical research phase. All of the company's drug candidates are discovered using the company's patents, unique compounds and integrated discovery engines. The company retains all options on its drug candidates.
Earnings Call
Q1/2025
Estimate EPS-3.79
Actual EPS-3.32
Estimate Revenue114.19M
Actual Revenue137.25M
Madrigal Pharmaceuticals Q1 2025: Unpacking Contradictions in Market Expectations, Patient Adoption, and Competitive Landscape
May 02,2025 12:49
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-3.63
Actual EPS-1.9
Estimate Revenue162.17M
Actual Revenue212.80M
Madrigal Pharmaceuticals' Q2 2025: Contradictions Surrounding GLP-1 Market Impact and Rezdiffra Growth
Aug 05,2025 05:41
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MDGL has released its 2025 Q3 earnings. EPS was reported at -5.08, versus the expected -1.99, missing expectations. The chart below visualizes how MDGL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MDGL has released its 2025 Q3 earnings report, with revenue of 287.27M, reflecting a YoY change of 362.03%, and net profit of -114.19M, showing a YoY change of -6.76%. The Sankey diagram below clearly presents MDGL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
